Pamukcu Rifat 4

What Happened Rifat Pamukcu, a director of Aprea Therapeutics (APRE), received equity awards on June 16, 2026: 3,135 shares (direct) and 12,555 derivative units (restricted stock units), both recorded at $0.00. The combined award totals 15,690 units; the derivative units are RSUs that will convert to common stock upon vesting. This was an award/grant (code A), not a purchase or sale.

Key Details

• Transaction date: June 16, 2026; Form 4 filed June 17, 2026 (timely).
• Prices: $0.00 per share/unit (awarded, no cash paid).
• Units granted: 3,135 shares + 12,555 derivative RSUs = 15,690 total.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes:
  • F1: The 12,555 derivative units are restricted stock units granted 6/16/2026 that will vest and be settled in common stock on 6/16/2027, subject to continued board service and possible acceleration.
  • F2: Reporting person serves as Manager Partner of ZNZ Holdings L.L.C.
  • F3: The filing notes an option vests in full on 6/16/2027 subject to continued service and potential acceleration.
• Filing timeliness: Reported the next day — not marked late.

Context Restricted stock unit awards are common director compensation and do not represent an immediate buy or sell signal; the RSUs only convert to tradable shares if/when they vest. Because these were grants (not open-market purchases), they primarily reflect compensation rather than direct insider confidence through buying stock. Pamukcu is a director (not a disclosed 10% owner in this summary).